Redeye comments on Thunderful Group ahead of its Q2 results (due 21 August).
Redeye updates its estimates after reviewing Tessin's Q2 report, which was in line with our expectat...
Redeye provides an update following Optomed’s Q2 report.
CapMan's Q2 adjusted EBIT was good on an underlying basis, with the Management company result in lin...
Redeye briefly comments on Maximum Entertainment’s announcement that the chairman of the board has a...
Redeye thinks the financial development in Q2 was weak, with the only positive surprise (product sal...
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 8 augusti år 2024 att Bolagets läkemedel Zeqmelit®...
Negative growth trend persists, but could improve from Q4'24e Potential for continued gross margin i...
Redeye continues to be positive to Bredband2 following a Q2 report in line with our estimates postin...
Redeye leaves a comment on Coegin Pharma’s announcement of having secured an exclusive agreement wit...
Redeye notes that Q2 sales and EBIT were lower than anticipated.
Raute’s Q2 revenue and earnings were a lot higher than we estimated as performance improved thanks t...
Redeye updates its view on Xspray following the Dasynoc CRL and the Q2 report.
CapMan reported Q2 Adj. EBIT of 5.8m, 4% below LSEG Data & Analytics consensus at EUR 6.
Redeye comments on G5’s Q2-results which were slighlty lower than our forecasts while the company re...
Q2 sales low due to delivery delay, SEK 12m already secure for H2 Elevated opex due to new and repla...
Ahead of Relais' Q2 report, due on 15 August, we make only minor underlying estimate revisions and i...
Redeye updates on Embracer ahead of Q1-results (due 15 Aug) where we expect a slow quarter with few ...
Obducat AB (publ) (”Obducat” eller ”Bolaget”) levererade ett starkt andra kvartal år 2024 trots utma...
Strong SBU and IBU sales helped DT Q2 earnings clearly above estimates as they made up for the weakn...
